A5010383897- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Virus-based gene therapy research
- Biosimilars and Bioanalytical Methods
- RNA Interference and Gene Delivery
- CRISPR and Genetic Engineering
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Biomedical Ethics and Regulation
Cornell University
2025
Weill Cornell Medicine
2025
Institut de Génétique Moléculaire de Montpellier
2021-2024
Centre National de la Recherche Scientifique
2021-2024
National Cancer Institute
2021-2024
National Institutes of Health
2021-2024
Université de Montpellier
2022-2024
Center for Cancer Research
2021-2022
Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have performed poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated (TAAs), limited persistence, and exhaustion. Here, we aimed identify optimal CARs against glypican 2 (GPC2) or CD276 (B7-H3), which were highly but heterogeneously expressed neuroblastoma (NB), a lethal extracranial tumor childhood. First, examined CAR expansion the presence targets by digital droplet PCR....
Abstract Immune checkpoint blockade (ICB) has yielded durable clinical responses which led to its FDA approval as a first-line therapy for melanoma and other malignancies. However, only ∼20-40% of patients show benefit when used monotherapies. This is mainly due inherent or acquired resistance these therapies within the tumor microenvironment (TME). There increasing evidence in pre-clinical studies that metabolism (e.g., glycolysis oxygen consumption (OXPHOS)) presents barrier anti-tumor...
CD19-directed CAR T-cells have been remarkably successful in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and transformed follicular (t-FL). In this cohort study, we treated 60 axicabtagene ciloleucel or tisagenlecleucel. Complete partial metabolic responses (CMR/PMR) were obtained 40% 23% of patients, respectively. After 6.9 months median follow-up, progression-free survival (mPFS) overall (mOS) estimated at 3.1 12.3 months, Statistical analyses...
Tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T cells have demonstrated remarkable success in the treatment of relapsed/refractory melanoma hematological malignancies, respectively. These treatments marked a pivotal shift cancer management. However, as "living drugs," their effectiveness is dependent on ability to proliferate persist patients. Recent studies indicate that mechanisms regulating these crucial functions, well cell's differentiation state, are...
Chimeric antigen receptor T cells (CART) have demonstrated curative potential for hematological malignancies, but the optimal manufacturing has not yet been determined and may differ across products. The first step, cell selection, removes contaminating types that can potentially suppress expansion transduction. While positive selection of CD4/CD8 after leukapheresis is often used in clinical trials, it modulate signaling cascades downstream these co-receptors; indeed, addition a...
Abstract Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable results in the treatment of hematological malignancies. However, several challenges remain, including achieving predictable efficacy and safety profiles extending this approach to solid tumors. As such, development approaches that generate engineered T cells with superior persistence are needed. Currently, generation CAR-T requires they be activated expanded ex vivo, generally via beads coated anti-CD3/anti-CD28...
<h3>Background</h3> A 17-year-old female with multiply relapsed B-cell ALL following CD19 CAR T-cells and blinatumomab was treated CD22 (NCT02315612) for marrow extramedullary disease (EMD). Following development of grade 2 cytokine release syndrome (on day +10) resolution, she experienced a rapidly rising lymphocyte count at 21 that further evaluated. <h3>Methods</h3> parental permission minor assent, the patient on National Cancer Institute IRB approved protocol phase 1 trial T-cells. To...